Hematology - European Medical Journal

This site is intended for healthcare professionals

Continue

Hematology

Filter
8 Mins
8 Aug 2017

The Role of Allograft in Acute Lymphoblastic Leukaemia, Including Alternate Donors

The management of acute lymphoblastic leukaemia (ALL) remains challenging.
12 Mins
8 Aug 2017

Double-Hit and Triple-Hit Lymphomas: New Perspectives for Their Classification

In 2016, an update on the classification of lymphoid neoplasm was published, and one of the modifications made focussed on B-cell lymphoma…
9 Mins
8 Aug 2017

Management of Adult Patients with Myelodysplastic Syndromes

The myelodysplastic syndromes form a heterogeneous group of clonal disorders with an increasing incidence in the elderly population and an emerging…
7 Mins
8 Aug 2017

Different Therapeutic Interventions and Mechanisms of Action of Antisickling Agents Currently in Use in Sickle Cell Disease Management

Sickle cell disease is a genetic disorder caused by sickle haemoglobin. In many forms of the disease, the red blood cells can change shape upon…
EMJ
4 Aug 2017

More Frequent Haemodialysis Improved Outcomes: The Wish Comes True at Home

This satellite symposium reviewed the challenges in providing dialysis to patients with kidney disease and outlined data supporting the effectiveness of…
3 Aug 2017

Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Lugano, Switzerland and San Diego, USA, 2 August, 2017 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products…
31 Jul 2017

Novel Antibody Therapy for the Treatment of Blood Cancers

CREATION of a new antibody by researchers may provide an effective alternative treatment for multiple blood cancers, including non-Hodgkin lymphoma…
11 Mins
28 Jul 2017

The Pivotal Role of Proteasome Inhibition in Myeloma Treatment

Prof Munshi opened the presentation with a brief video highlighting the interaction of myeloma cells with the bone microenvironment…
We’ve noticed you’re accessing
from North/South America.